

Peter Altevogt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5217897/publications.pdf>

Version: 2024-02-01

137
papers

14,860
citations

18482

62
h-index

19190

118
g-index

138
all docs

138
docs citations

138
times ranked

18046
citing authors

#	ARTICLE	IF	CITATIONS
1	STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. , 2022, 10, e004384.		21
2	Novel insights into the function of <scp>CD24</scp>: A driving force in cancer. International Journal of Cancer, 2021, 148, 546-559.	5.1	100
3	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cellular Immunology, 2021, 359, 104254.	3.0	141
4	miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells. Cancers, 2021, 13, 964.	3.7	5
5	DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. American Journal of Pathology, 2021, 191, 618-630.	3.8	7
6	Reduced Placental CD24 in Preterm Preeclampsia Is an Indicator for a Failure of Immune Tolerance. International Journal of Molecular Sciences, 2021, 22, 8045.	4.1	7
7	Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. Journal of the National Cancer Institute, 2020, 112, 507-515.	6.3	33
8	SOX2 in development and cancer biology. Seminars in Cancer Biology, 2020, 67, 74-82.	9.6	186
9	IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma. , 2020, 8, e000949.		59
10	HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma. Cancers, 2020, 12, 3761.	3.7	7
11	Recent insights into the role of <scp>L1CAM</scp> in cancer initiation and progression. International Journal of Cancer, 2020, 147, 3292-3296.	5.1	17
12	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 2020, 21, 2367.	4.1	34
13	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. Cancer Research, 2019, 79, 4715-4728.	0.9	97
14	Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies. Oncotarget, 2019, 10, 1662-1663.	1.8	7
15	Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. British Journal of Cancer, 2019, 120, 16-25.	6.4	504
16	CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. Cancer Research, 2018, 78, 157-167.	0.9	127
17	Targeting SOX2 in anticancer therapy. Expert Opinion on Therapeutic Targets, 2018, 22, 983-991.	3.4	60
18	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Frontiers in Immunology, 2018, 9, 1310.	4.8	404

#	ARTICLE	IF	CITATIONS
19	SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. <i>International Journal of Cancer</i> , 2018, 143, 3131-3142.	5.1	66
20	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 5505-5516.	8.2	193
21	Procoagulant extracellular vesicles in amniotic fluid. <i>Translational Research</i> , 2017, 184, 12-20.e1.	5.0	22
22	Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. <i>Histochemistry and Cell Biology</i> , 2017, 147, 565-574.	1.7	42
23	L1CAM in the Early Enteric and Urogenital System. <i>Journal of Histochemistry and Cytochemistry</i> , 2017, 65, 21-32.	2.5	9
24	<i>TMPRSS2:ERG</i> gene fusion variants induce TGF- β 2 signaling and epithelial to mesenchymal transition in human prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 25115-25130.	1.8	23
25	L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma. <i>Pathology and Oncology Research</i> , 2016, 22, 863-868.	1.9	31
26	L1CAM in human cancer. <i>International Journal of Cancer</i> , 2016, 138, 1565-1576.	5.1	148
27	L1-CAM is commonly expressed in testicular germ cell tumours. <i>Journal of Clinical Pathology</i> , 2016, 69, 460-462.	2.0	3
28	Evaluating L1CAM expression in human endometrial cancer using qRT-PCR. <i>Oncotarget</i> , 2016, 7, 40221-40232.	1.8	9
29	Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients. <i>BMC Clinical Pathology</i> , 2015, 15, 19.	1.8	16
30	Extracellular Vesicles from Ovarian Carcinoma Cells Display Specific Glycosignatures. <i>Biomolecules</i> , 2015, 5, 1741-1761.	4.0	64
31	Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT. <i>International Journal of Cancer</i> , 2015, 136, E326-39.	5.1	37
32	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. <i>Oncolmmunology</i> , 2015, 4, e1008371.	4.6	227
33	A novel method for measuring cellular antibody uptake using imaging flow cytometry reveals distinct uptake rates for two different monoclonal antibodies targeting L1. <i>Journal of Immunological Methods</i> , 2015, 423, 70-77.	1.4	15
34	Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions. <i>Clinical Cancer Research</i> , 2015, 21, 1010-1018.	7.0	11
35	Single-Molecule Localization Microscopy allows for the analysis of cancer metastasis-specific miRNA distribution on the nanoscale. <i>Oncotarget</i> , 2015, 6, 44745-44757.	1.8	22
36	A Standardized Staining Protocol for L1CAM on Formalin-Fixed, Paraffin-Embedded Tissues Using Automated Platforms. <i>International Journal of Biological Markers</i> , 2014, 29, 180-183.	1.8	9

#	ARTICLE	IF	CITATIONS
37	L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor. <i>BMC Cancer</i> , 2014, 14, 958.	2.6	38
38	Lack of CD24 expression in mice reduces the number of leukocytes in the colon. <i>Immunology Letters</i> , 2014, 161, 140-148.	2.5	4
39	Extracellular Vesicle-Mediated Transfer of Genetic Information between the Hematopoietic System and the Brain in Response to Inflammation. <i>PLoS Biology</i> , 2014, 12, e1001874.	5.6	312
40	L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. <i>Molecular Oncology</i> , 2014, 8, 982-997.	4.6	34
41	Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 87-100.	3.3	20
42	Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. <i>Seminars in Cancer Biology</i> , 2014, 28, 51-57.	9.6	63
43	miR-21-3p is a positive regulator of L1CAM in several human carcinomas. <i>Cancer Letters</i> , 2014, 354, 455-466.	7.2	39
44	Combined targeting of TGF- β 1 and integrin β 3 impairs lymph node metastasis in a mouse model of non-small-cell lung cancer. <i>Molecular Cancer</i> , 2014, 13, 112.	19.2	35
45	Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30. <i>Cancer Research</i> , 2014, 74, 3429-3440.	0.9	169
46	Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. <i>Oncotarget</i> , 2014, 5, 462-472.	1.8	63
47	Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-associated antigens. <i>BMC Cancer</i> , 2013, 13, 156.	2.6	15
48	Exosomes as a Potential Tool for a Specific Delivery of Functional Molecules. <i>Methods in Molecular Biology</i> , 2013, 1049, 495-511.	0.9	61
49	Body Fluid Exosomes Promote Secretion of Inflammatory Cytokines in Monocytic Cells via Toll-like Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2013, 288, 36691-36702.	3.4	203
50	Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 107-121.	2.5	18
51	CD24 polymorphisms in breast cancer: impact on prognosis and risk. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 927-937.	2.5	19
52	L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1142-1150.	6.3	185
53	L1 Cell Adhesion Molecule as a Potential Therapeutic Target in Murine Models of Endometriosis Using a Monoclonal Antibody Approach. <i>PLoS ONE</i> , 2013, 8, e82512.	2.5	11
54	Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. <i>PLoS Biology</i> , 2012, 10, e1001450.	5.6	1,064

#	ARTICLE	IF	CITATIONS
55	EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF- κ B activation. <i>Carcinogenesis</i> , 2012, 33, 1919-1929.	2.8	75
56	Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. <i>Carcinogenesis</i> , 2012, 33, 84-93.	2.8	18
57	L1CAM. <i>Cell Adhesion and Migration</i> , 2012, 6, 374-384.	2.7	168
58	Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. <i>Cancer Letters</i> , 2012, 319, 66-82.	7.2	49
59	Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice. <i>Gastroenterology</i> , 2012, 143, 1375-1384.e5.	1.3	82
60	CD24 controls Src/STAT3 activity in human tumors. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 3863-3879.	5.4	69
61	CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 819-831.	2.5	21
62	CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 27-38.	3.3	50
63	N-Glycosylation of total cellular glycoproteins from the human ovarian carcinoma SKOV3 cell line and of recombinantly expressed human erythropoietin. <i>Glycobiology</i> , 2011, 21, 376-386.	2.5	65
64	Linking L1CAM-mediated signaling to NF- κ B activation. <i>Trends in Molecular Medicine</i> , 2011, 17, 178-187.	6.7	51
65	Glycoconjugate expression in adenoid cystic carcinoma of the salivary glands: up-regulation of L1 predicts fatal prognosis. <i>Histopathology</i> , 2011, 59, 299-307.	2.9	9
66	Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage. <i>Gynecologic Oncology</i> , 2011, 122, 437-446.	1.4	248
67	Interaction and uptake of exosomes by ovarian cancer cells. <i>BMC Cancer</i> , 2011, 11, 108.	2.6	513
68	L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. <i>Molecular Cancer</i> , 2011, 10, 127.	19.2	82
69	Body fluid derived exosomes as a novel template for clinical diagnostics. <i>Journal of Translational Medicine</i> , 2011, 9, 86.	4.4	612
70	Contractile Forces Contribute to Increased Glycosylphosphatidylinositol-anchored Receptor CD24-facilitated Cancer Cell Invasion. <i>Journal of Biological Chemistry</i> , 2011, 286, 34858-34871.	3.4	65
71	Full-Length L1CAM and Not Its Δ 27 Splice Variant Promotes Metastasis through Induction of Gelatinase Expression. <i>PLoS ONE</i> , 2011, 6, e18989.	2.5	18
72	Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor- β 1 (TGF- β 2)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. <i>International Journal of Oncology</i> , 2011, 38, 257-66.	3.9	12

#	ARTICLE	IF	CITATIONS
73	L1CAM malfunction in the nervous system and human carcinomas. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 2425-2437.	5.4	122
74	L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. <i>BMC Molecular Biology</i> , 2010, 11, 64.	3.0	34
75	Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. <i>Journal of Pathology</i> , 2010, 220, 551-561.	4.5	90
76	Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. <i>Laboratory Investigation</i> , 2010, 90, 1102-1116.	3.7	62
77	Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma. <i>Cancer Research</i> , 2010, 70, 2504-2515.	0.9	62
78	Inhibition of cell proliferation, adhesion, and invasion with an anti-L1-cell adhesion molecule monoclonal antibody in an in vitro endometriosis model. <i>Fertility and Sterility</i> , 2010, 94, 1102-1104.	1.0	9
79	Elevated L1CAM expression in precursor lesions and primary and metastatic tissues of pancreatic ductal adenocarcinoma. <i>Oncology Reports</i> , 2010, 24, 909-15.	2.6	28
80	Up-regulation of L1CAM in Pancreatic Duct Cells Is Transforming Growth Factor β 1 and Slug-Dependent: Role in Malignant Transformation of Pancreatic Cancer. <i>Cancer Research</i> , 2009, 69, 4517-4526.	0.9	90
81	Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. <i>Journal of Molecular Medicine</i> , 2009, 87, 99-112.	3.9	35
82	Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. <i>Cancer Letters</i> , 2009, 278, 73-81.	7.2	265
83	Expression and prognostic value of L1-CAM in breast cancer. <i>Oncology Reports</i> , 2009, 22, 1109-17.	2.6	41
84	Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/ β -secretase activity. <i>Biochemical Journal</i> , 2009, 420, 391-402.	3.7	89
85	Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. <i>Journal of Cellular Biochemistry</i> , 2008, 103, 1783-1797.	2.6	104
86	The RGD integrin binding site in human L1-CAM is important for nuclear signaling. <i>Experimental Cell Research</i> , 2008, 314, 2411-2418.	2.6	31
87	Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. <i>Cancer Letters</i> , 2008, 261, 193-204.	7.2	25
88	Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2008, 1780, 905-913.	2.4	68
89	CD24 induces localization of β 1 integrin to lipid raft domains. <i>Biochemical and Biophysical Research Communications</i> , 2008, 365, 35-41.	2.1	74
90	Transfer of T Cell Surface Molecules to Dendritic Cells upon CD4+ T Cell Priming Involves Two Distinct Mechanisms. <i>Journal of Immunology</i> , 2008, 181, 3965-3973.	0.8	29

#	ARTICLE	IF	CITATIONS
91	Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA. <i>Cancer Research</i> , 2008, 68, 2803-2812.	0.9	140
92	Evidence for secretion of Cu,Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. <i>Neuroscience Letters</i> , 2007, 428, 43-46.	2.1	200
93	Copper-67 Radioimmunotherapy and Growth Inhibition by Anti-L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis. <i>Clinical Cancer Research</i> , 2007, 13, 603-611.	7.0	73
94	Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. <i>International Journal of Cancer</i> , 2007, 120, 2625-2634.	5.1	45
95	L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. <i>Gynecologic Oncology</i> , 2007, 104, 461-469.	1.4	83
96	Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. <i>Gynecologic Oncology</i> , 2007, 107, 563-571.	1.4	335
97	CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. <i>Journal of Cell Science</i> , 2006, 119, 314-325.	2.0	170
98	L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. <i>Cancer Letters</i> , 2006, 239, 212-226.	7.2	44
99	Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. <i>Human Pathology</i> , 2006, 37, 1000-1008.	2.0	72
100	Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. <i>International Journal of Oncology</i> , 2006, 28, 551.	3.3	17
101	A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. <i>Biochemical Journal</i> , 2006, 393, 609-618.	3.7	217
102	Exosomes: From biogenesis and secretion to biological function. <i>Immunology Letters</i> , 2006, 107, 102-108.	2.5	775
103	The adhesion molecule L1 (CD171) promotes melanoma progression. <i>International Journal of Cancer</i> , 2006, 119, 549-555.	5.1	87
104	Efficient Inhibition of Intra-Peritoneal Tumor Growth and Dissemination of Human Ovarian Carcinoma Cells in Nude Mice by Anti-L1-Cell Adhesion Molecule Monoclonal Antibody Treatment. <i>Cancer Research</i> , 2006, 66, 936-943.	0.9	140
105	L1 augments cell migration and tumor growth but not β 3 integrin expression in ovarian carcinomas. <i>International Journal of Cancer</i> , 2005, 115, 658-665.	5.1	64
106	Cleavage of L1 in Exosomes and Apoptotic Membrane Vesicles Released from Ovarian Carcinoma Cells. <i>Clinical Cancer Research</i> , 2005, 11, 2492-2501.	7.0	174
107	Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival. <i>Clinical Cancer Research</i> , 2005, 11, 6574-6581.	7.0	145
108	L1 Is Sequentially Processed by Two Differently Activated Metalloproteases and Presenilin-3-Secretase and Regulates Neural Cell Adhesion, Cell Migration, and Neurite Outgrowth. <i>Molecular and Cellular Biology</i> , 2005, 25, 9040-9053.	2.3	212

#	ARTICLE	IF	CITATIONS
109	L1, a novel target of β -catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. <i>Journal of Cell Biology</i> , 2005, 168, 633-642.	5.2	335
110	L1 (CD171) as a novel biomarker for ovarian and endometrial carcinomas. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 455-462.	3.1	14
111	Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas). <i>Journal of Cutaneous Pathology</i> , 2003, 30, 363-368.	1.3	32
112	L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. <i>Cancer Letters</i> , 2003, 189, 237-247.	7.2	108
113	L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. <i>Lancet, The</i> , 2003, 362, 869-875.	13.7	252
114	ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. <i>FASEB Journal</i> , 2003, 17, 292-294.	0.5	199
115	CD24 expression is a new prognostic marker in breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4906-13.	7.0	213
116	Critical amino acid residues of the β 4 subunit for α 4 β 7 integrin function. <i>Journal of Cellular Biochemistry</i> , 2001, 83, 304-319.	2.6	8
117	Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. <i>Journal of Cell Biology</i> , 2001, 155, 661-674.	5.2	357
118	Role of Src Kinases in the ADAM-mediated Release of L1 Adhesion Molecule from Human Tumor Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 15490-15497.	3.4	163
119	Characterization of the L1-Neurocan-binding Site. <i>Journal of Biological Chemistry</i> , 2000, 275, 34478-34485.	3.4	39
120	Integrin Leukocyte Function-associated Antigen-1-mediated Cell Binding Can Be Activated by Clustering of Membrane Rafts. <i>Journal of Biological Chemistry</i> , 1999, 274, 36921-36927.	3.4	154
121	Integrin and Neurocan Binding to L1 Involves Distinct Ig Domains. <i>Journal of Biological Chemistry</i> , 1999, 274, 24602-24610.	3.4	69
122	CD24 is a marker for human breast carcinoma. <i>Cancer Letters</i> , 1999, 143, 87-94.	7.2	92
123	CD24 mediates rolling of breast carcinoma cells on P-selectin. <i>FASEB Journal</i> , 1998, 12, 1241-1251.	0.5	258
124	The L1 Adhesion Molecule Supports β 2-Integrin-Mediated Migration of Human Tumor Cells and Activated T Lymphocytes. <i>Biochemical and Biophysical Research Communications</i> , 1997, 232, 236-239.	2.1	33
125	Mouse CD24 as a Signaling Molecule for Integrin-Mediated Cell Binding: Functional and Physical Association with src-Kinases. <i>Biochemical and Biophysical Research Communications</i> , 1997, 234, 330-334.	2.1	50
126	CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells. <i>Blood</i> , 1997, 89, 3385-3395.	1.4	293

#	ARTICLE	IF	CITATIONS
127	The cell adhesion molecule L1: species- and cell-type-dependent multiple binding mechanisms. <i>Differentiation</i> , 1997, 61, 143-150.	1.9	54
128	Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. <i>BBA - Proteins and Proteomics</i> , 1997, 1337, 287-294.	2.1	50
129	A role for the VLA-4 integrin in the activation of human memory B cells. <i>European Journal of Immunology</i> , 1997, 27, 2757-2764.	2.9	26
130	L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to α _v β ₃ integrin. <i>European Journal of Immunology</i> , 1996, 26, 2508-2516.	2.9	103
131	Evidence for Cis-Interaction and Cooperative Signalling by the Heat-stable Antigen Nectadrin (murine) Tj ETQq1 1 0.784314 rgBT /Over 993-1004.	2.6	57
132	Heat-stable antigen (CD24) as ligand for mouse P-selectin. <i>International Immunology</i> , 1994, 6, 1027-1036.	4.0	110
133	Heat-stable antigen/CD24 on mouse T lymphocytes: evidence for a costimulatory function. <i>European Journal of Immunology</i> , 1994, 24, 731-737.	2.9	82
134	CD2: a functional adhesion molecule on murine B cells, involved in interleukin-4-induced aggregation. <i>European Journal of Immunology</i> , 1993, 23, 888-892.	2.9	10
135	L1 adhesion molecule on mouse leukocytes: regulation and involvement in endothelial cell binding. <i>European Journal of Immunology</i> , 1993, 23, 2927-2931.	2.9	39
136	Expression and function of the neural cell adhesion molecule L1 in mouse leukocytes. <i>European Journal of Immunology</i> , 1992, 22, 1199-1205.	2.9	59
137	The effects of anti-CD2 antibodies on the differentiation of mouse thymocytes. <i>European Journal of Immunology</i> , 1989, 19, 951-954.	2.9	26